<DOC>
	<DOCNO>NCT02868281</DOCNO>
	<brief_summary>This study aim evaluate effectiveness Asthma Control Test ( ACT ) guide treatment compare usual care asthma subject China . It design assist Chinese subject physicians improve adherence guideline inclusion ACT patient 's asthma management plan . This prospective , multicentre , cluster-randomized , open-label 24-week study . In cluster-randomization design , study center , consider cluster , randomize either ACT guide treatment group control group ( usual care group ) . For subject recruit ACT center , treat base ACT score . If ACT score equal ( = ) 25 equal ( &gt; = ) 3 month treatment stepped-down ; ACT score &gt; =20 , less ( &lt; ) 25 ACT=25 &lt; 3 month change ACT score le ( &lt; = ) 19 treatment stepped-up . For subject recruit control center , treat base doctor 's subjective judgment . Assignment treatment occur , treatment intervention provide study . A total 528 asthma subject plan study . The randomization stratify accord Tier hospital ( Tier 3 verse Tier 2 ) .</brief_summary>
	<brief_title>Asthma Control Test Guided Treatment Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bronchial Diseases</mesh_term>
	<criteria>Inclusion criterion study centre ( cluster ) : General practice Located Shanghai Providing asthma care Inclusion Criteria subject Visit 0 Age : 18 70 inclusive Gender : Male Female Documented clinical history asthma least 6 month prior Visit 0 At Visit 0 , demonstrable reversible increase FEV1 least 12 percent ( % ) ( &gt; =200 milliliter [ mL ] ) , 15 minute inhale shortacting bronchodilator ; time last 2 year documentary evidence reversible increase FEV1 least 12 % ( &gt; =200 mL ) 15 minute inhale shortacting bronchodilator ; demonstrable reversible increase morning PEF least 15 % ( &gt; =200 mL ) either spontaneously inhalation shortacting bronchodilator History use inhaled corticosteroid alone combine inhaled longacting beta two agonist ( LABA ) treatment within 1 year prior Visit 0 Subjects must ACT score &lt; 20 Visit 0 Subject must able read , comprehend , record information Chinese A sign date write informed consent must obtain subject prior study participation History Lifethreatening asthma : Defined protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure within last 6 month Visit 0 Subjects severe unstable asthma , ACT score &lt; 12 Visit 0 , history repeat severe exacerbation ( 3 per year ) and/or severe exacerbation previous 6 week Visit 0 . A current evidence clinically significant uncontrolled medical condition disease ( e.g. , psychological disorder , mental deficiency , severe hepatic renal dysfunction , malignancy ) Current smoker exsmoker 10 packyear history smoke Current clinically significant respiratory disease asthma , ( e.g. , lung cancer , lung fibrosis , sarcoidosis , tuberculosis , chronic obstructive pulmonary disease ) History alcohol medication abuse History upper low respiratory tract infection within 4 week prior Visit 0 Enrolled asthma clinic outpatient service past 12 month provide comprehensive asthma management Subjects history adverse reaction include immediate delay hypersensitivity intranasal , inhale , systemic corticosteroid LABA therapy component inhalation powder ( e.g. , lactose ) Visit 0 . In addition , subject history severe milk protein allergy , opinion Investigator , contraindicate subject 's participation also exclude Females currently pregnant lactate Subjects receive follow medication 6 week precede visit 0 : oral/parenteral corticosteroid , oral beta twoagonists slowrelease bronchodilator , sodium cromoglycate nedocromil sodium , ketotifen , anticholinergic , antiImmunoglobulinE treatment Subjects comply poorly asthma treatment opinion investigator/inability unwillingness take asthma medication ( noncompliance ) , follow direction unable complete write paper daily record card selfrating questionnaire Concurrently participate another clinical study subject expose investigational noninvestigational medication device , participate clinical trial receive investigational product within 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) Subjects contraindication asthma medication take study period , exclude account special warning precaution within label asthma medication treat study period Affiliation Investigator Site : Is investigator , subinvestigator , study coordinator , employee participate investigator study site , immediate family member afore mention involve study Subjects plan move away geographical area study conduct study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cluster Randomization</keyword>
	<keyword>Peak Expiratory Flow</keyword>
	<keyword>Forced Expiratory Volume</keyword>
	<keyword>Standardized Asthma Quality Life Questionnaire</keyword>
	<keyword>Asthma Control Test</keyword>
</DOC>